Page 21 - Let them speak Towards a patient reported outcome measure set for

General introduction
References
1. (EC) R. No 141/2000 of the European Parliament and of the Council of 16 December 1999
on orphan medicinal products. Official Journal [Available from: https://eur-lex.europa.eu/legal-
content/EN/TXT/?uri=uriserv:OJ.L_.1999.155.01.0001.01.ENG.
2. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C, Lanneau V, et al. Estimating
cumulative point prevalence of rare diseases: analysis of the Orphanet database. European
journal of human genetics. 2020;28(2):165–73.
3. American Psychiatric Association D, Association AP. Diagnostic and statistical manual of
mental disorders: DSM-5: American psychiatric association Washington, DC; 2013.
4. Maulik PK, Mascarenhas MN, Mathers CD, Dua T, Saxena S. Prevalence of intellectual
disability: a meta-analysis of population-based studies. Research in developmental disabilities.
2011;32(2):419–36.
5. Wang J, Wang Y, Wang L, Chen WY, Sheng M. The diagnostic yield of intellectual disability:
combined whole genome low-coverage sequencing and medical exome sequencing. BMC
medical genomics. 2020;13:1–15.
6. Pekeles H, Accogli A, Boudrahem-Addour N, Russell L, Parente F, Srour M. Diagnostic yield of
intellectual disability gene panels. Pediatric neurology. 2019;92:32–6.
7. Williams K, Jacoby P, Whitehouse A, Kim R, Epstein A, Murphy N, et al. Functioning, participation,
and quality of life in children with intellectual disability: an observational study. Developmental
Medicine & Child Neurology. 2021;63(1):89–96.
8. Dingemans AJ, Jansen S, van Reeuwijk J, de Leeuw N, Pfundt R, Schuurs-Hoeijmakers J, et
al. Prevalence of comorbidities in individuals with neurodevelopmental disorders from the
aggregated phenomics data of 51,227 pediatric individuals. Nature Medicine. 2024:1–10.
9. Tye C, Mcewen FS, Liang H, Underwood L, Woodhouse E, Barker ED, et al. Long‐term cognitive
outcomes in tuberous sclerosis complex. Developmental Medicine & Child Neurology.
2020;62(3):322–9.
10. Muscogiuri G, Barrea L, Faggiano F, Maiorino M, Parrillo M, Pugliese G, et al. Obesity in
Prader–Willi syndrome: Physiopathological mechanisms, nutritional and pharmacological
approaches. Journal of Endocrinological Investigation. 2021;44(10):2057–70.
11. Boot E, Bassett AS, Marras C. 22q11. 2 deletion syndrome–associated Parkinson’s disease.
Movement disorders clinical practice. 2019;6(1):11–6.
12. Butcher NJ, Marras C, Pondal M, Rusjan P, Boot E, Christopher L, et al. Neuroimaging and
clinical features in adults with a 22q11. 2 deletion at risk of Parkinson’s disease. Brain.
2017;140(5):1371–83.
13. von der Lippe C, Neteland I, Feragen KB. Children with a rare congenital genetic disorder: A
systematic review of parent experiences. Orphanet Journal of Rare Diseases. 2022;17(1):375.
14. Polder J, Meerding WJ, Bonneux L, Maas Pvd. Healthcare costs of intellectual disability in
the Netherlands: a cost‐of‐illness perspective. Journal of Intellectual Disability Research.
2002;46(2):168–78.
15. Krahn GL, Hammond L, Turner A. A cascade of disparities: health and health care access for
people with intellectual disabilities. Mental retardation and developmental disabilities research
reviews. 2006;12(1):70–82.
16. Mishra S, Venkatesh M. Rare disease clinical trials in the European Union: navigating regulatory
and clinical challenges. Orphanet journal of rare diseases. 2024;19(1):285.
17. Edwards G, Jones C, Pearson E, Royston R, Oliver C, Tarver J, et al. Prevalence of anxiety
symptomatology and diagnosis in syndromic intellectual disability: A systematic review and
meta-analysis. Neuroscience & Biobehavioral Reviews. 2022;138:104719.
18. Borland R, Hu N, Tonge B, Einfeld S, Gray K. Participation in sport and physical activity in adults
with intellectual disabilities. Journal of Intellectual Disability Research. 2020;64(12):908–22.
19. Health USDo, Human Services FDACfDE, Research, Health USDo, Human Services FDACfBE,
Research, et al. Guidance for industry: patient-reported outcome measures: use in medical
product development to support labeling claims: draft guidance. Health and Quality of Life
Outcomes. 2006;4(1):79.
1
19